Drug Profile
IGT 13
Latest Information Update: 28 May 2001
Price :
$50
*
At a glance
- Originator Prescient NeuroPharma
- Class Antineoplastics
- Mechanism of Action DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2001 No-Development-Reported for Cancer in Canada (Unknown route)
- 07 Mar 2001 IGT Pharma has merged with Neurotrophic Bioscience to form Prescient NeuroPharma
- 03 Dec 1998 New profile